China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

NewsGuard 100/100 Score

China PharmaHub Corp. ("PharmaHub"), recently merged with World Wide Relics (OTC Bulletin Board: WRLC), which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., ("Yongkon"), a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.  PharmaHub was authorized by Yongkon as its appointed agent to identify pharmaceutical products and medical devices in the U.S. and negotiate the terms to obtain the rights to sell such products and devices in China.

Yongkon is an established and GMP certified pharmaceutical company with focus on the identification, development, manufacture, sales and distribution of Chinese traditional medicine, biopharmaceuticals and medical equipment with its focus on antiviral drugs, bio-engineering drugs and anticancer drugs.  Yongkon manufactures and sells over 90 GMP approved drugs in China. Its leading product, Xiaojinwan, is a well known Traditional Chinese Medicine treating breast hyperplasia, thyroid and benign tumor.  Yongkon has a marketing force of over 400 sales personnel in 34 sales offices in over 31 provinces and cities as well as in Beijing, Tianjin, Shanghai and Chongqing.  

Richard Lui, CEO of PharmaHub, said "We are glad to gain another capable strategic partner in China. In less than one year of founding, we have successfully established partnerships with Research Institute and Government Agencies in China. We have now taken an important step in the partnership with entrepreneurs.  With the accomplishment of this major milestone, we've successfully created a chain of command in the commercialization of technologies we identify and bring to China.  Yongkon supports our structure with an established sales and marketing team and nationwide sales channel."

Lui continued, "This is another successful demonstration of our HUB model, of partnering with successful enterprises and working together to bring life saving pharmaceuticals and medical devices to the world.  PharmaHub's relationships with the New Drug Center and the Sichuan Technical Exchange Center, and now with Chengdu Yongkon, represent PharmaHub's drive to become  an innovator in the pharmaceutical and medical device industry."

Source:

China PharmaHub Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global end-to-end solutions partner to life sciences organisations, AscellaHealth, joins Manchester Science Park